DOCKET NO.: CHIR-0054 - 2 - PATENT-REISSUE

contain said heterologous DNA sequence, wherein said heterologous DNA sequence [is a human sequence encoding insulin-like growth factor (hIGF)] comprises a nucleic acid sequence selected from the group consisting of:

- (a) 5'-GGA CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT
 CTT CAG TTC GTG TGT GGA GAC AGG GGC TTT TAT TTC AAC AAG CCC ACA
 GGG TAT GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA GGT ATC GTG GAT
 GAG TGC TGC TTC CGG AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC
 GCA CCC CTC AAG CCT GCC AAG TCA GCT-3';
- (b) 5'-GCT TAC CGC CCC AGT GAG ACC CTG TGC GGC GGG GAG CTG
 GTG GAC ACC CTC CAG TTC GTC TGT GGG GAC CGC GGC TTC TAC TTC AGC
 AGG CCC GCA AGC CGT GTG AGC CGT CGC AGC CGT GGC ATC GTT GAG GAG
 TGC TGT TTC CGC AGC TGT GAC CTG GCC CTC CTG GAG ACG TAC TGT GCT
 ACC CCC GCC AAG TCC GAG-3';
 - (c) a nucleic acid sequence [sequences] complementary to (a) or (b); [and]
- (d) <u>a fragment</u> [fragments] of (a)[, (b)] or (b) [(c)] that [are] <u>is</u> at least 18 bases in length [and which will selectively hybridize to human genomic DNA encoding hIGF]; and
 - (e) a fragment of (c) that is at least 18 bases in length.
- 11. (Four times amended) A composition according to claim 9 wherein said [hIGF is hIGF-I and said heterologous DNA] <u>nucleic acid</u> sequence is <u>sequence</u> (b).

Please amend added claims 27, 28, 44, and 46 to read as follows:

27. (Amended) A method of producing a polypeptide comprising the amino acid sequence of Fig. 1 in a suitable host cell transformed with a polynucleotide encoding said

DOCKET NO.: CHIR-0054 - 3 - PATENT-REISSUE

polypeptide, wherein said polynucleotide comprises the <u>following</u> nucleic acid sequence [of claim 4], wherein U can also be T:

S'-CUG GCG CUG UGC CUG CUC ACC UUC ACC AGC UCU GCC ACG GCU

GGA CCG GAG ACG CUC UGC GGG GCU GAG CUG GUG GAU GCU CUU CAG

UUC GUG UGU GGA GAC AGG GGC UUU UAU UUC AAC AAG CCC ACA GGG

UAU GGC UCC AGC AGU CGG AGG GCG CCU CAG ACA GGU AUC GUG GAU

GAG UGC UGC UUC CGG AGC UGU GAU CUA AGG AGG CUG GAG AUG UAU

UGC GCA CCC CUC AAG CCU GCC AAG UCA GCU CGC UCU GUC CGU GCC CAG

CGC CAC ACC GAC AUG CCC AAG ACC CAG AAG GAA GUA CAU UUG AAG AAC

GCA AGU AGA GGG AGU GCA GGA AAC AAG AAC UAC AGG AUG-3',

which method comprises expressing said polynucleotide in said host cell.

28. (Amended) A method of producing a polypeptide comprising the amino acid sequence of Fig. 2 in a suitable host cell transformed with a polynucleotide encoding said polypeptide, wherein said polynucleotide comprises the <u>following</u> nucleic acid sequence [of claim 5], wherein U can also be T:

5'-AUG GGA AUC CCA AUG GGG AAG UCG AUG CUG GUG CUU CUC ACC

UUC UUG GCC UUC GCC UCG UGC UGC AUU GCU GCU UAC CGC CCC AGU GAG

ACC CUG UGC GGC GGG GAG CUG GUG GAC ACC CUC CAG UUC GUC UGU

GGG GAC CGC GGC UUC UAC UUC AGC AGG CCC GCA AGC CGU GUG AGC CGU

CGC AGC CGU GGC AUC GUU GAG GAG UGC UGU UUC CGC AGC UGU GAC

CUG GCC CUC CUG GAG ACG UAC UGU GCU ACC CCC GCC AAG UCC GAG AGG

GAC GUG UCG ACC CCU CCG ACC GUG CUU CCG GAC AAC UUC CCC AGA UAC

CCC GUG GGC AAG UUC UUC CAA UAU GAC ACC UGG AAG CAG UCC ACC CAG

DOCKET NO.: CHIR-0054 - 4 - PATENT-REISSUE

which method comprises expressing said polynucleotide in said host cell.

- 44. (Amended) A vector comprising a nucleic acid sequence selected from the group consisting of the <u>following nucleic acid sequences:</u> [(a), (b), (c), (d), and (e) of claim: 1]
- (a) 5'-GGA CCG GAG ACG CUC UGC GGG GCU GAG CUG GUG GAU GCU
 CUU CAG UUC GUG UGU GGA GAC AGG GGC UUU UAU UUC AAC AAG CCC
 ACA GGG UAU GGC UCC AGC AGU CGG AGG GCG CCU CAG ACA GGU AUC
 GUG GAU GAG UGC UUC CGG AGC UGU GAU CUA AGG AGG CUG GAG
 AUG UAU UGC GCA CCC CUC AAG CCU GCC AAG UCA GCU-3', wherein U can also
 be T;
- (b) 5'-GCU UAC CGC CCC AGU GAG ACC CUG UGC GGC GGG GAG CUG

 GUG GAC ACC CUC CAG UUC GUC UGU GGG GAC CGC GGC UUC UAC UUC AGC

 AGG CCC GCA AGC CGU GUG AGC CGU CGC AGC CGU GGC AUC GUU GAG

 GAG UGC UGU UUC CGC AGC UGU GAC CUG GCC CUC CUG GAG ACG UAC

 UGU GCU ACC CCC GCC AAG UCC GAG-3', wherein U can also be T;
 - (c) a nucleic acid sequence complementary to (a) or (b);
 - (d) a fragment of (a) or (b) that is at least 18 bases in length; and
 - (e) a fragment of (c) that is at least 18 bases in length.
 - 46. (Amended) An expression vector comprising a polynucleotide encoding a

DOCKET NO.: CHIR-0054 -5- PATENT-REISSUE

polypeptide, wherein said polypeptide comprises an amino acid sequence of Fig. 1 or Fig. 2, or [fragments] <u>fragment</u> thereof, wherein said [polynucleotide comprises] <u>amino acid</u> <u>sequence, or fragment thereof, is encoded by</u> a nucleic acid sequence selected from the group consisting of the <u>following nucleic acid sequences:</u> [(a), (b), and (d) of claim 1]

(a) 5'-GGA CCG GAG ACG CUC UGC GGG GCU GAG CUG GUG GAU GCU
CUU CAG UUC GUG UGU GGA GAC AGG GGC UUU UAU UUC AAC AAG CCC
ACA GGG UAU GGC UCC AGC AGU CGG AGG GCG CCU CAG ACA GGU AUC
GUG GAU GAG UGC UUC CGG AGC UGU GAU CUA AGG AGG CUG GAG
AUG UAU UGC GCA CCC CUC AAG CCU GCC AAG UCA GCU-3', wherein U can also
be T;

(b) 5'-GCU UAC CGC CCC AGU GAG ACC CUG UGC GGC GGG GAG CUG
GUG GAC ACC CUC CAG UUC GUC UGU GGG GAC CGC GGC UUC UAC UUC AGC
AGG CCC GCA AGC CGU GUG AGC CGU CGC AGC CGU GGC AUC GUU GAG
GAG UGC UGU UUC CGC AGC UGU GAC CUG GCC CUC CUG GAG ACG UAC
UGU GCU ACC CCC GCC AAG UCC GAG-3', wherein U can also be T; and

(c) a fragment of (a) or (b) that is at least 18 bases in length.